Collection of peripheral blood hematopoietic stem cells from ABO major incompatible allogeneic donors

WM Li,C Zhang,Y You,LH Xia,P Zou

DOI: https://doi.org/10.3321/j.issn:1673-8225.2007.28.012

2007-01-01

Abstract:Aim: To evaluate the efficiency of the blood cell separator for harvesting of peripheral blood hematopoietic stem cells (PBSC) from ABO major incompatible allogeneic donors and the safety of PBSC transplantation to the patients without removal of erythrocytes. Methods: The experiment was done in Department of Hematology, Union Hospital Affiliated to Huazhong University of Science and Technology from October 1998 to October 2006. 1 Subjects of the experiment: Twenty-three healthy HLA-matched donor of allogeneic hematopoietic stem cell transplantation were enrolled. Twenty-one of them were related donor and two were unrelated donor from the data bank of Chinese hematopoietic stem cell donor. ABO blood groups of recipient/donor pairs of these twenty-three patients was O/A in fifteen and O/B in eight. Among the patients, 9 were acute lymphocytic leukemia, 8 were acute non-lymphocytic leukemia, 5 were chronic myelocytic leukemia and one was aplastic anemia. The experiment was approved by Medical Ethics Committee and got permission of all the patients. 2 Methods of the experiment: All of the 23 donors were given hypodermic granulocyte colony-stimulating factor (G-CSF) 5 μg/kg per day for mobilization. When leukocyte count was more than 20×10 9 L -1 and the ratio of mononuclear cells was more than 10% at the fifth day, peripheral blood hematopoietic stem cells were collected by Cobe Spectra blood cell separator with auto-peripheral blood stem cell program. The mean circulation volume was 9 210 mL and the mean inlet rate was 42 mL/min. Collection in each donor was undergone twice, totally forty-six collections were done. To prevent adverse effects such as hypocalcemia, numbness and spasm, 10% calcium gluconate was given intravenously or orally during collection or calcium tablets were given three days before collection. Prophylactic medicines were given before stem cells infusion to prevent hemolytic reaction and protect renal function in 23 recipients. Each patient received infusion twice, a total of 46 infusions were performed. 3 Experimental evaluation: Sample from collection bag for nucleated cell count, hematocrit (HCT), CD34 positive cell count and trypan blue stain. Vital signs, color of the urine and other hemolysis correlated adverse effects were observed after each infusion. Results: 1 Adverse effects during PBSC collection: Among the 46 collections, natrium citricum complex related hypocalcemia occurred in 4 (8.7%)cases, and the manifestations of hypocalcemia including anesthesia of limbs and lips, gastrointestinal tract reactions, chest distress and dizziness, etc. All of the above symptoms could be cured by oral 10% calcium gluconate. An average of 50 mL 10% calcium gluconate was given and 80 mL for maximum. Angio-cranial nerve related symptoms such as pale and sweating occurred in one of the donors (2.17%). 2 Adverse effects of PBSC infusion to the recipients: The mean yield of nucleated cells was (3.76:±0.89)×10 8/kg, and CD34 +, cell was (3.23±0.89)x 10 6/kg. Trypan blue exclusion rate was 100% for all the samples. The mean hemoglobin in the collection was (18±4) g/L. The collections were infused into the recipients without removal of erythrocytes. Haemolytic reaction was only observed in one infusion and cured by dexamethasone, 5% NaHCO 3 and more infusion solutions. Hematopoietic functions were re-established in all of the patients. Conclusion: Enough PBSC can be harvested by blood cell separator from ABO major incompatible allogeneic donors and the PBSC collections can be safely infused to the patients without removal of erythrocytes.